Ensign Peak Advisors
ORMP icon

Ensign Peak Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Ensign Peak Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,760
Closed -$8K – 2343
2022
Q2 		$8K Hold
1,760
– – ﹤0.01% 2149
2022
Q1 		$15K Buy
+1,760
New +$18K ﹤0.01% 2185

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors's ORMP Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 1,760 shares — an estimated $8K sold.

Ensign Peak Advisors first reported a position in ORMP in Q1 2022 and held it in 2 quarters. The position peaked at $15K in Q1 2022. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 1,760 Oramed Pharmaceuticals shares in Q3 2022, an estimated $8K.
  • Ensign Peak Advisors first reported a position in Oramed Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Ensign Peak Advisors's Oramed Pharmaceuticals position peaked at $15K in Q1 2022.
  • 71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.